Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains
CODX(NASDAQ:CODX) SALT LAKE CITY, Sept. 11, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has performed an in silico analysis of...
Report Highlights Growth in AI Biomarker Monitoring as Industry Giant's GPUs Power Next-Gen Platform
NVDA(NASDAQ:NVDA) MarketNewsUpdates News Commentary NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The global Diagnostic Biomarker market is experiencing unprecedented growth and is projected to continue to see substantial growth in years to come. A recent report from the (NIH) National Library of Medicine...
Contrast Enhanced Ultrasound Imaging Helps Streamline Hospital Workflows, Survey Says
CHICAGO--(BUSINESS WIRE)-- #CEUS--Contrast enhanced ultrasound (CEUS) often streamlines hospital workflows while providing safe, accurate and cost-effective diagnostic imaging, according to responses to a survey described today at a medical conference in Chicago. Survey respondents said that CEUS offers reliable diagnostic information in real time using ultrasound systems that are readily available in many medical centers – providing an improved “same-day” diagnosis up-front and often eliminating the d
Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
BXS(NYSE:BXS) SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--CyPath® Lung identifies incidentally found ground-glass lung nodules, leading to early diagnosis and timely treatment.
Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering
DGX(NYSE:DGX) New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced...
MyOme Expands Proactive Health Portfolio with Launch of Type 2 Diabetes Integrated Polygenic Risk Score (iPRS)™
MENLO PARK, Calif., Sept. 3, 2025 /PRNewswire/ -- MyOme, a leading clinical whole genome testing and polygenic risk modelling (PRS) company, today announced the launch of its Type 2 Diabetes (T2D) Integrated Polygenic Risk Score™ (iPRS). The new report, available as part of MyOme's...
New Analysis Shows Corrected T1 (cT1) Is the Most Appropriate Diagnosis and Monitoring Tool for Widespread Adoption of Resmetirom Treatment in the United States
GILD(NASDAQ:GILD) WASHINGTON--(BUSINESS WIRE)-- #LiverMultiScan--Economic analysis shows LiverMultiScan is the most appropriate diagnosis and monitoring tool for scalable adoption of resmetirom in the United States.
U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--U.S. Medicine magazine features CyPath® Lung in its latest issue, highlighting its potential to improve lung cancer detection and lower costs.
Arima Genomics Introduces Aventa Lymphoma Test to Resolve Diagnostic Uncertainty in B- and T-Cell Lymphomas
CARLSBAD, Calif.--(BUSINESS WIRE)-- #ArimaGenomics--Arima Genomics introduces the Aventa Lymphoma Test, designed to resolve diagnostic uncertainty in B- and T-cell lymphomas.
Molecular Designs Launches Urogenital Microbiota Panel to Detect Pathogens and Antibiotic Resistance
Urogenital Microbiota with ABX 53 Simplicity Panel™ delivers same-day research use only results, identifying 28 organisms and 25 resistance markers in a streamlined, lab-ready format BIRMINGHAM, Ala., Sept. 3, 2025 /PRNewswire/ -- Molecular Designs, a developer and manufacturer of...
3-minute EEG Test Reliably Detects Memory Impairment, Enabling Earlier Alzheimer's Diagnosis
Breakthrough research from the University of Bath and the University of Bristol that demonstrates the real-world efficacy of a passive EEG test in identifying memory decline years before a clinical diagnosis, is being developed as a screening tool by Cumulus Neuroscience BELFAST, Northern...
Inflammatix Data in Journal of Clinical Microbiology Validate Accuracy, Robustness, and Ease of Use of TriVerity™ Test System
Publication demonstrates superior analytical performance of TriVerity in assessing patients with suspected acute infection or sepsis SUNNYVALE, Calif., Sept. 2, 2025 /PRNewswire/ -- Inflammatix, a pioneering host response diagnostics company, today announced the publication of analytical...
QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
QGEN(NYSE:QGEN) GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with the easiest workflow available to customers worldwide. The new system, which received clearance from the U.S. Food and Drug Administration (FDA), is designed to meet the needs of hospitals and reference laboratories seeking highly automat
American Regent® Launches Gvoke VialDx™ (glucagon injection)
First concentrated, ready-to-dilute liquid glucagon available for diagnostic procedures SHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire/ -- American Regent, Inc.® is pleased to announce the commercial launch and availability of Gvoke VialDx™ (glucagon injection). Gvoke VialDx (glucagon...
C2N Diagnostics Expands the PrecivityAD2™ Alzheimer’s Disease Blood Test Intended Use to Patients 50 Years and Older
ST. LOUIS--(BUSINESS WIRE)-- #Alzheimers--Clinicians worried about early-onset Alzheimer’s disease in patients with cognitive concerns between the ages of 50 and 55 years can now prescribe the PrecivityAD2™ blood test to aid in the diagnosis of the neurological disorder for that expanded population. The test helps healthcare professionals in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and helps inform medical management and treatment decisions. C2N Diagnosti
Science Bytes Podcast Explores How Diagnostics Can Help Protect Students and Communities
QDELSAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- With classrooms once again filled and respiratory virus season beginning, QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, is sharing timely public health insights from Dr. Jonathan Temte, Professor of Family...
Alpha-1 Foundation Launches Innovative New Model for Centralized Detection
CORAL GABLES, Fla., Aug. 20, 2025 /PRNewswire/ -- The Alpha-1 Foundation (A1F) is excited to announce the formation of AlphaDetect, a new non-profit subsidiary of A1F, to lead a centralized effort to identify individuals with Alpha-1 Antitrypsin Deficiency (Alpha-1 or AATD). A1F is...
Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease
LHLumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta...
Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation
BIXTBOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is proud to announce a major scientific milestone: the publication of Body Oxygen Homeostasis and Mitochondrial Function from Animal Models to Clinical Applications by Prof. Avraham Mayevsky, a key advisor to Bioxytran. This groundbreaking work dives deep into the science of oxygen regulation and mitochondrial health – revealing transformative insights that could redefine treatment for stroke, Alzheimer’s, and other critical conditions.
https://link.springer.com/book/10.1007/978-3-031-94113-9
Ultima Genomics' ppmSeq™ Delivers Unmatched Combination of Sensitivity and Efficiency for Whole-Genome MRD Detection
New bioRxiv paper showcases: Tumor-informed ctDNA detection down to one-in-ten million (10-7), which extends well beyond the limits of currently available clinical minimal residual disease (MRD) assays Superior double-stranded DNA (dsDNA) recovery rates versus other technologies, reducing...